CTOs on the Move

Relypsa

www.relypsa.com

 
Relypsa is a biopharmaceutical company leading the discovery, development and commercialization of polymer-based medicines to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patient lives or even be life-threatening. Relypsa was founded in October 2007 and is headquartered in Redwood City, Calif. In 2015, we received FDA approval for our first medicine, which was developed based on our polymer technology platform for the treatment of hyperkalemia. In September 2016, Relypsa became a Vifor Pharma company. Today, we have more than 400 employees united by a passion for improving people’s lives.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.relypsa.com
  • 100 Cardinal Way
    Redwood City, CA USA 94063
  • Phone: 650.421.9500

Executives

Name Title Contact Details
Bill Yates
 Chief Information Officer and Vice President Profile

Similar Companies

Vysis

Vysis, Inc. is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Janpix

Janpix is discovering and developing monovalent small molecule degraders of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and the relevance of STAT3 & STAT5, in particular, in certain cancers is well validated. Although disrupting the function of STAT proteins is very challenging, Janpix has developed new chemistry to address this complex problem.

Mana Therapeutics

MANA was founded in November 2018, based on the research and human proof-of-concept clinical trials conducted by Dr. Catherine Bollard and her team at Children`s National Hospital (CNH) in Washington, D.C., along with colleagues at Johns Hopkins Medical Center.

Signum Biosciences Inc

Signum Biosciences Inc is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inipharm

At Inipharm, we`re building on novel insights and applying our chemistry expertise to develop therapies for patients with liver disease. Inipharm`s lead program is focused on small-molecules to target the activity of HSD17B13, a highly validated, genetically defined target for multiple severe liver and related diseases.